The burden of HBV infection remains high and new strategies to improve HBV vaccination and therapy are needed. Key research in 2016 highlights the efficacy of current approaches and proposes new concepts for some of the immunological defects that need to be overcome for HBV functional cure.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088 (2016).
Chang, M. H. et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151, 472–480.e1 (2016).
Pan, C. Q. et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N. Engl. J. Med. 374, 2324–2334 (2016).
Lok, A. S. et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J. Hepatol. 65, 509–516 (2016).
Tian, Y., Kuo, C.-F., Akbari, O. & Ou, J.-H. J. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity 44, 1204–1214 (2016).
Zeng, Z. et al. Interferon-γ facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance. J. Exp. Med. 213, 1079–1093 (2016).
Hong, M. et al. Trained immunity in newborn infants of HBV-infected mothers. Nat. Commun. 6, 6558 (2015).
Mason, W. S. et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 151, 986–998.e4 (2016).
Schurich, A. et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 16, 1243–1252 (2016).
Zhang, X. et al. In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. J. Clin. Invest. 126, 1079–1092 (2016).
Acknowledgements
M.K.M. is supported by a Wellcome Trust Senior Investigator Award and a Medical Research Council project grant. A.B. is supported by a Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/013/2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.K.M. lab has received research funding from Gilead and Roche, and has served as a consultant and on advisory boards for BMS, Galapagos, Gilead, ITS, Medimmune, Roche and Transgene. A.B. collaborates and receives research support from Gilead. He acted as a consultant and served on the advisory boards of Abivax, Gilead, Humabs BioMed, Jansseen-Cilag, Medimmune. A.B. is also a co-founder of LION TCR, a biotech company developing T-cell receptors for treatment of virus-related cancers and chronic viral diseases.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Maini, M., Bertoletti, A. Global and immunotherapeutic insights into hepatitis B. Nat Rev Gastroenterol Hepatol 14, 71–72 (2017). https://doi.org/10.1038/nrgastro.2016.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.196
This article is cited by
-
TCR-grafted T cells restore antiviral immunity
Nature Reviews Gastroenterology & Hepatology (2019)
-
A comparative study on the characterization of hepatitis B virus quasispecies by clone-based sequencing and third-generation sequencing
Emerging Microbes & Infections (2017)